A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
134actual
Sites
52
Countries
Argentina, Austria, Belgium +14
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-07-20 | actual | When the study began enrolling |
| Primary completion | 2025-05-07 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-02-28 | estimated | The whole study's end, after follow-up |
| First posted | 2019-12-09 | actual | When this record first appeared on the registry |
| Results posted | 2026-07-10 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-07-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hypereosinophilic Syndrome
Interventions
- Biological: Benralizumab
- Biological: Placebo
Primary outcome
what the primary-completion date above is the date OFTime to First HES Worsening/Flare During the DB Treatment Period
measured DB period (Baseline to Week 24)
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2024-09-26 · 4.7 MB · Prot_000.pdf
Statistical Analysis Planposted 2025-02-05 · 5.4 MB · SAP_003.pdf
Publications
- PMID 41917160 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed